Jack Khattar - Supernus Pharmaceuticals Founder, CEO and President and Director
| SUPN Stock | USD 30.83 0.56 1.85% |
CEO
Mr. Jack A. Khattar is President, Chief Executive Officer, Secretary, Director of the company. He is the founder of our Company and has served as our President, Chief Executive Officer and Secretary and a Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions during that time as a board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc executive committee. Prior to that, Mr. Khattar served as an executive officer and the chairman of the management committee at CIMA Labs Inc., a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck Co., Novartis, Playtex and Kodak in various locations, including the United States, Europe and the Middle East. Mr. Khattar served on the board of Rockville Economic Development, Inc. from 2003 until 2013. He currently serves on the board of directors of Prevacus, Inc., a privatelyheld development stage biotechnology company, and on the advisory board of New Rhein Healthcare, a private equity firm. Mr. Khattar also serves as Chairman of the board of directors of scPharmaceuticals, a publicly traded pharmaceutical company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. Mr. Khattar leadership, executive, managerial, business and pharmaceutical company experience, along with his more than 30 years of industry experience in the development and commercialization of pharmaceutical products and drug delivery technologies, qualify him to be a director. since 2005.
| Age | 63 |
| Tenure | 19 years |
| Professional Marks | MBA |
| Address | 9715 Key West Avenue, Rockville, MD, United States, 20850 |
| Phone | 301 838 2500 |
| Web | https://www.supernus.com |
Jack Khattar Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jack Khattar against Supernus Pharmaceuticals stock is an integral part of due diligence when investing in Supernus Pharmaceuticals. Jack Khattar insider activity provides valuable insight into whether Supernus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Supernus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Supernus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jack Khattar over two weeks ago Acquisition by Jack Khattar of 17300 shares of Scpharmaceuticals at 11.71 subject to Rule 16b-3 |
Supernus Pharmaceuticals Management Efficiency
At this time, Supernus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 7th of May 2024, Return On Capital Employed is likely to grow to 0.01, while Return On Equity is likely to drop 0. At this time, Supernus Pharmaceuticals' Intangibles To Total Assets are very stable compared to the past year. As of the 7th of May 2024, Fixed Asset Turnover is likely to grow to 22.16, while Other Current Assets are likely to drop about 8.5 M. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| James Hall | Lifecore Biomedical | 61 | |
| Richard Nanula | Lucy Scientific Discovery | 63 | |
| Gary Sr | Organogenesis Holdings | 69 | |
Management Performance
| Return On Equity | 0.0015 | ||||
| Return On Asset | 0.0056 |
Supernus Pharmaceuticals Leadership Team
Elected by the shareholders, the Supernus Pharmaceuticals' board of directors comprises two types of representatives: Supernus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Supernus. The board's role is to monitor Supernus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Supernus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Supernus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Padmanabh Bhatt, Chief Scientific Officer and Sr. VP of Intellectual Property | ||
| Timothy Dec, Senior CFO | ||
| Tami Martin, VP Affairs | ||
| Jack Khattar, Founder, CEO and President and Director | ||
| Kevin Anderson, Compliance Officer | ||
| RN Esq, Senior Affairs | ||
| Taylor Raiford, Senior Sales | ||
| Bryan Roecklein, Senior Development | ||
| Jonathan Rubin, VP Officer | ||
| Todd MBA, Senior Access | ||
| Frank Mottola, GMP Quality | ||
| MBA MD, Senior Officer |
Supernus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Supernus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0015 | ||||
| Return On Asset | 0.0056 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 1.47 B | ||||
| Shares Outstanding | 54.97 M | ||||
| Shares Owned By Insiders | 5.02 % | ||||
| Shares Owned By Institutions | 94.98 % | ||||
| Number Of Shares Shorted | 4.68 M | ||||
| Price To Earning | 15.25 X |
Currently Active Assets on Macroaxis
When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.